Compare VSAT & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VSAT | VERA |
|---|---|---|
| Founded | 1986 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 1.5B |
| IPO Year | 1996 | 2021 |
| Metric | VSAT | VERA |
|---|---|---|
| Price | $34.38 | $50.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | $33.00 | ★ $76.60 |
| AVG Volume (30 Days) | 1.5M | ★ 1.8M |
| Earning Date | 02-05-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,582,796,000.00 | N/A |
| Revenue This Year | $5.08 | N/A |
| Revenue Next Year | $3.47 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.23 | N/A |
| 52 Week Low | $7.36 | $18.53 |
| 52 Week High | $43.59 | $56.05 |
| Indicator | VSAT | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 48.02 | 67.50 |
| Support Level | $33.72 | $47.22 |
| Resistance Level | $37.46 | $56.05 |
| Average True Range (ATR) | 1.85 | 2.51 |
| MACD | -0.02 | -0.38 |
| Stochastic Oscillator | 35.08 | 55.88 |
Viasat Inc provides bandwidth technologies and services in three segments: communication services and defense and advanced technologies. The communication services segment provides a wide range of broadband and narrowband communications solutions across government and commercial mobility markets, as well as for residential and enterprise fixed broadband customers: and the defense and advanced technologies segment develops and offers a diverse array of resilient, vertically integrated solutions to government and commercial customers, leveraging core technical competencies in encryption, cyber security, tactical gateways, modems and waveforms. A large majority of the firm's revenue is generated from communication services segment.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.